0704 Comparative Efficacy of Tonic Motor Activation for Medication-Naïve and Dopaminergic-Treated Restless Legs Syndrome

Mark Buchfuhrer,Haramandeep Singh,Joseph Ojile,Fiona Baker,Jonathan Charlesworth

DOI: https://doi.org/10.1093/sleep/zsae067.0704

IF: 6.313

2024-04-20

SLEEP

Abstract:Abstract Introduction Due to augmentation, exposure to dopaminergic treatment induces worsening of restless legs syndrome (RLS) and reduces response to gabapentinoid medications, frequently leading to refractory RLS. Tonic motor activation (TOMAC) is a noninvasive neurostimulation therapy indicated for refractory RLS. We tested if response to TOMAC is affected by dopaminergic treatment. Methods We retrospectively analyzed two clinical trials that each enrolled a mixture of adults with primary moderate-severe RLS who were medication-naïve (drug-naïve), treated with dopamine agonist medication (DA-treated), or other medication history (not analyzed here). There was no drug washout. Trial 1 (NCT04700683, mean age 55.6, 56% female) employed crossover design with 2-weeks of TOMAC and sham control in randomized order. Trial 2 (NCT05214963, mean age 56.0, 69% female) employed parallel design with participants randomized to 2-weeks of TOMAC or sham. Participants were instructed to self-administer 30-minutes of treatment when they experienced RLS symptoms. RLS severity was assessed based on change to mean International RLS Scale (IRLS) score. P-values were determined with two-factor ANOVA for treatment assignment and medication history. Results RLS severity improved similarly for drug-naïve and DA-treated RLS patients during TOMAC relative to sham treatment. In Trial 1, mean IRLS change during TOMAC was -4.2 points for drug-naïve (sham: 0.0 points; n=13) and -4.5 points for DA-treated (sham: -1.4; n=14) groups; treatment assignment main effect was significant (p=0.011) and there was no interaction between medication history and treatment assignment effects (p=0.679). In Trial 2, mean IRLS change during TOMAC was -6.3 points for drug-naïve (sham: -1.4; n=25) and -8.6 points for DA-treated (sham: -4.9; n=14); treatment assignment main effect was significant (p=0.010) and there was no interaction between medication history and treatment assignment effects (p=0.701). For all groups, IRLS change was >3 points different for TOMAC compared to sham, the minimal clinically significant difference. Conclusion There was no difference in TOMAC efficacy between DA-treated and medication-naïve RLS. TOMAC treatment consistently resulted in greater RLS improvement than sham control. This differs from gabapentinoids, which have reduced effectiveness following DA treatment. These results may indicate an advantage of TOMAC over gabapentinoids for refractory RLS. Support (if any) Sponsored by Noctrix Health. NCT05214963 supported by NIH/NINDS R44NS117294.

neurosciences,clinical neurology